Sutro Biopharma Appoints Dr. Hans Peter Gerber As Chief
09/19/23, 12:42 PM
Location
san francisco
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 -- Sutro Biopharma, Inc. , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates , today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023
Company Info
Location
san francisco, california, united states
Additional Info
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.